Description
Nutriband, Inc. is primarily engaged in the development of a portfolio of transdermal pharmaceutical products, contract research and development services and the manufacture of transdermal, topical and coated products.
The Company's lead product is its AVERSA technology. AVERSA abuse deterrent transdermal technology incorporates aversive agents to prevent the Abuse, DiVERsion, MiSuse and Accidental exposure of drugs with abuse potential specifically Opioids.
The Company's first application for AVERSA is for its abuse deterrent fentanyl transdermal patch, which the Company is developing to provide clinicians and patients with an extended-release chronic pain relief. In addition, it is developing a portfolio of transdermal pharmaceutical products to deliver commercially available drugs or biologics that are typically delivered by injection. The Company's subsidiaries include Nutriband Ltd., 4P Therapeutics LLC and Pocono Pharmaceuticals Inc.